Abnormalities of E- and P-cadherin and catenin (β-, γ-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia

Abnormal expression of cadherins and catenins plays a critical role in the initiation and progression of multiple human tumours. This study aimed to evaluate the immunoreactivity of E‐ and P‐cadherin, β‐ and γ‐catenin, and p120ctn in premalignant and malignant endometrial lesions and to correlate th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of pathology 2003-04, Vol.199 (4), p.471-478
Hauptverfasser: Moreno-Bueno, Gema, Hardisson, David, Sarrió, David, Sánchez, Carolina, Cassia, Raúl, Prat, Jaime, Herman, James G, Esteller, Manel, Matías-Guiu, Xavier, Palacios, José
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 478
container_issue 4
container_start_page 471
container_title The Journal of pathology
container_volume 199
creator Moreno-Bueno, Gema
Hardisson, David
Sarrió, David
Sánchez, Carolina
Cassia, Raúl
Prat, Jaime
Herman, James G
Esteller, Manel
Matías-Guiu, Xavier
Palacios, José
description Abnormal expression of cadherins and catenins plays a critical role in the initiation and progression of multiple human tumours. This study aimed to evaluate the immunoreactivity of E‐ and P‐cadherin, β‐ and γ‐catenin, and p120ctn in premalignant and malignant endometrial lesions and to correlate their membranous expression with clinicopathological features. In addition, we examined whether or not LOH and promoter hypermethylation of the CDH1 gene were associated with E‐cadherin expression and clinicopathological variables. Finally, we studied the frequency of β‐catenin mutations in premalignant endometrial lesions. Immunohistochemical staining was performed in 21 atypical endometrial hyperplasias (AEHs), 95 endometrioid carcinomas (EECs), and 33 non‐endometrioid carcinomas (NEECs). Reduced E‐cadherin expression was observed in 57.8% of the cases, being more frequent in NEECs (87.1%, p = 0.001) and carcinomas of more advanced stage (85.7% of stage III–IV carcinomas, p = 0.01). LOH of CDH1 gene was found in 57.1% of NEECs but only in 22.5% of EECs (p = 0.011) and showed a trend towards association with reduced E‐cadherin expression (p = 0.089). CDH1 promoter hypermethylation was found in 21.2% of endometrial carcinomas but was not associated with clinicopathological or immunohistochemical variables. Reduced expression of β‐ and γ‐catenin and p120ctn was found in 76.1%, 94.3%, and 63.6% of the cases, respectively, being more frequent in lesions with reduced E‐cadherin expression. In addition, β‐catenin, but not γ‐catenin or p120ctn expression, was associated with the histology of the lesion, since it was reduced in 35% of AEHs, 80.3% of EECs, and 96.9% of NEECs (p = 0.000). Mutations in exon 3 of the β‐catenin gene, associated with β‐catenin nuclear expression, were detected in 3 (14.0%) AEH, a frequency similar to that previously reported in this series of ECs. Finally, upregulation of P‐cadherin was observed in 28.6% of cases. This alteration was associated with the histology of the lesion, since it was found in 9.5% of AEHs, 27.7% of EECs, and 46.2% of NEECs (p = 0.021). Copyright © 2003 John Wiley & Sons, Ltd.
doi_str_mv 10.1002/path.1310
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73089611</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73089611</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4860-36dad5b48f74acb29ba4ce293fef32bc522cf3118ed8721481f21caed759955a3</originalsourceid><addsrcrecordid>eNqFkc1u1DAQxy0Eape2B14A5QKiUt167MRJjqvSbpFWdJGKOFqOM9Ea8lU7K7rPwZvAe_SZcHYjygVx8njmNx_6_wl5BewcGOMXvR7W5yCAPSMzYLmkeZbL52QWapyKGNJD8tL7r4yxPE-SA3IIXIoERDYjP-ZF27lG13aw6KOuiq5opNsyWlGjyzU62-6-Rg_Yhvjd4096Fj3-olPibFftgTMztKcRPvQOvbddGwUY27JrcHBW12FAa9Dt6L_Tetj21oRgve3R9bX2Vh-TF5WuPZ5M7xH5fH11d3lDl7eLD5fzJTVxJhkVstRlUsRZlcbaFDwvdGyQ56LCSvDCJJybSgBkWGYphziDioPRWKbJKIMWR-Ttfm7vuvsN-kE11husa91it_EqFSzoCPBfELI0kXGSBvB0DxrXee-wUr2zjXZbBUyNVqnRKjVaFdjX09BN0WD5RE7eBODNBGgfFKpcUND6Jy6WEI4bl17sue-2xu2_N6rV_O5mWk33HdYP-PCnQ7tvSqYiTdSXjwslVwt4fy2X6pP4DaJovBY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18756457</pqid></control><display><type>article</type><title>Abnormalities of E- and P-cadherin and catenin (β-, γ-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia</title><source>MEDLINE</source><source>Wiley Online Library</source><creator>Moreno-Bueno, Gema ; Hardisson, David ; Sarrió, David ; Sánchez, Carolina ; Cassia, Raúl ; Prat, Jaime ; Herman, James G ; Esteller, Manel ; Matías-Guiu, Xavier ; Palacios, José</creator><creatorcontrib>Moreno-Bueno, Gema ; Hardisson, David ; Sarrió, David ; Sánchez, Carolina ; Cassia, Raúl ; Prat, Jaime ; Herman, James G ; Esteller, Manel ; Matías-Guiu, Xavier ; Palacios, José</creatorcontrib><description>Abnormal expression of cadherins and catenins plays a critical role in the initiation and progression of multiple human tumours. This study aimed to evaluate the immunoreactivity of E‐ and P‐cadherin, β‐ and γ‐catenin, and p120ctn in premalignant and malignant endometrial lesions and to correlate their membranous expression with clinicopathological features. In addition, we examined whether or not LOH and promoter hypermethylation of the CDH1 gene were associated with E‐cadherin expression and clinicopathological variables. Finally, we studied the frequency of β‐catenin mutations in premalignant endometrial lesions. Immunohistochemical staining was performed in 21 atypical endometrial hyperplasias (AEHs), 95 endometrioid carcinomas (EECs), and 33 non‐endometrioid carcinomas (NEECs). Reduced E‐cadherin expression was observed in 57.8% of the cases, being more frequent in NEECs (87.1%, p = 0.001) and carcinomas of more advanced stage (85.7% of stage III–IV carcinomas, p = 0.01). LOH of CDH1 gene was found in 57.1% of NEECs but only in 22.5% of EECs (p = 0.011) and showed a trend towards association with reduced E‐cadherin expression (p = 0.089). CDH1 promoter hypermethylation was found in 21.2% of endometrial carcinomas but was not associated with clinicopathological or immunohistochemical variables. Reduced expression of β‐ and γ‐catenin and p120ctn was found in 76.1%, 94.3%, and 63.6% of the cases, respectively, being more frequent in lesions with reduced E‐cadherin expression. In addition, β‐catenin, but not γ‐catenin or p120ctn expression, was associated with the histology of the lesion, since it was reduced in 35% of AEHs, 80.3% of EECs, and 96.9% of NEECs (p = 0.000). Mutations in exon 3 of the β‐catenin gene, associated with β‐catenin nuclear expression, were detected in 3 (14.0%) AEH, a frequency similar to that previously reported in this series of ECs. Finally, upregulation of P‐cadherin was observed in 28.6% of cases. This alteration was associated with the histology of the lesion, since it was found in 9.5% of AEHs, 27.7% of EECs, and 46.2% of NEECs (p = 0.021). Copyright © 2003 John Wiley &amp; Sons, Ltd.</description><identifier>ISSN: 0022-3417</identifier><identifier>EISSN: 1096-9896</identifier><identifier>DOI: 10.1002/path.1310</identifier><identifier>PMID: 12635138</identifier><identifier>CODEN: JPTLAS</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Ltd</publisher><subject>atypical endometrial hyperplasia ; beta Catenin ; Biological and medical sciences ; Cadherins - metabolism ; catenin ; Catenins ; Cell Adhesion Molecules - metabolism ; Cytoskeletal Proteins - genetics ; Cytoskeletal Proteins - metabolism ; Disease Progression ; E-cadherin ; endometrial cancer ; Endometrial Hyperplasia - genetics ; Endometrial Hyperplasia - metabolism ; Endometrial Hyperplasia - pathology ; Endometrial Neoplasms - genetics ; Endometrial Neoplasms - metabolism ; Endometrial Neoplasms - pathology ; Female ; Female genital diseases ; Gynecology. Andrology. Obstetrics ; Humans ; Loss of Heterozygosity ; Medical sciences ; Mutation ; Neoplasm Proteins - metabolism ; P-cadherin ; Phosphoproteins - metabolism ; Precancerous Conditions - genetics ; Precancerous Conditions - metabolism ; Precancerous Conditions - pathology ; Trans-Activators - genetics ; Trans-Activators - metabolism ; Tumors ; β-catenin mutation</subject><ispartof>The Journal of pathology, 2003-04, Vol.199 (4), p.471-478</ispartof><rights>Copyright © 2003 John Wiley &amp; Sons, Ltd.</rights><rights>2003 INIST-CNRS</rights><rights>Copyright 2003 John Wiley &amp; Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4860-36dad5b48f74acb29ba4ce293fef32bc522cf3118ed8721481f21caed759955a3</citedby><cites>FETCH-LOGICAL-c4860-36dad5b48f74acb29ba4ce293fef32bc522cf3118ed8721481f21caed759955a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpath.1310$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpath.1310$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14616117$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12635138$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moreno-Bueno, Gema</creatorcontrib><creatorcontrib>Hardisson, David</creatorcontrib><creatorcontrib>Sarrió, David</creatorcontrib><creatorcontrib>Sánchez, Carolina</creatorcontrib><creatorcontrib>Cassia, Raúl</creatorcontrib><creatorcontrib>Prat, Jaime</creatorcontrib><creatorcontrib>Herman, James G</creatorcontrib><creatorcontrib>Esteller, Manel</creatorcontrib><creatorcontrib>Matías-Guiu, Xavier</creatorcontrib><creatorcontrib>Palacios, José</creatorcontrib><title>Abnormalities of E- and P-cadherin and catenin (β-, γ-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia</title><title>The Journal of pathology</title><addtitle>J. Pathol</addtitle><description>Abnormal expression of cadherins and catenins plays a critical role in the initiation and progression of multiple human tumours. This study aimed to evaluate the immunoreactivity of E‐ and P‐cadherin, β‐ and γ‐catenin, and p120ctn in premalignant and malignant endometrial lesions and to correlate their membranous expression with clinicopathological features. In addition, we examined whether or not LOH and promoter hypermethylation of the CDH1 gene were associated with E‐cadherin expression and clinicopathological variables. Finally, we studied the frequency of β‐catenin mutations in premalignant endometrial lesions. Immunohistochemical staining was performed in 21 atypical endometrial hyperplasias (AEHs), 95 endometrioid carcinomas (EECs), and 33 non‐endometrioid carcinomas (NEECs). Reduced E‐cadherin expression was observed in 57.8% of the cases, being more frequent in NEECs (87.1%, p = 0.001) and carcinomas of more advanced stage (85.7% of stage III–IV carcinomas, p = 0.01). LOH of CDH1 gene was found in 57.1% of NEECs but only in 22.5% of EECs (p = 0.011) and showed a trend towards association with reduced E‐cadherin expression (p = 0.089). CDH1 promoter hypermethylation was found in 21.2% of endometrial carcinomas but was not associated with clinicopathological or immunohistochemical variables. Reduced expression of β‐ and γ‐catenin and p120ctn was found in 76.1%, 94.3%, and 63.6% of the cases, respectively, being more frequent in lesions with reduced E‐cadherin expression. In addition, β‐catenin, but not γ‐catenin or p120ctn expression, was associated with the histology of the lesion, since it was reduced in 35% of AEHs, 80.3% of EECs, and 96.9% of NEECs (p = 0.000). Mutations in exon 3 of the β‐catenin gene, associated with β‐catenin nuclear expression, were detected in 3 (14.0%) AEH, a frequency similar to that previously reported in this series of ECs. Finally, upregulation of P‐cadherin was observed in 28.6% of cases. This alteration was associated with the histology of the lesion, since it was found in 9.5% of AEHs, 27.7% of EECs, and 46.2% of NEECs (p = 0.021). Copyright © 2003 John Wiley &amp; Sons, Ltd.</description><subject>atypical endometrial hyperplasia</subject><subject>beta Catenin</subject><subject>Biological and medical sciences</subject><subject>Cadherins - metabolism</subject><subject>catenin</subject><subject>Catenins</subject><subject>Cell Adhesion Molecules - metabolism</subject><subject>Cytoskeletal Proteins - genetics</subject><subject>Cytoskeletal Proteins - metabolism</subject><subject>Disease Progression</subject><subject>E-cadherin</subject><subject>endometrial cancer</subject><subject>Endometrial Hyperplasia - genetics</subject><subject>Endometrial Hyperplasia - metabolism</subject><subject>Endometrial Hyperplasia - pathology</subject><subject>Endometrial Neoplasms - genetics</subject><subject>Endometrial Neoplasms - metabolism</subject><subject>Endometrial Neoplasms - pathology</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Loss of Heterozygosity</subject><subject>Medical sciences</subject><subject>Mutation</subject><subject>Neoplasm Proteins - metabolism</subject><subject>P-cadherin</subject><subject>Phosphoproteins - metabolism</subject><subject>Precancerous Conditions - genetics</subject><subject>Precancerous Conditions - metabolism</subject><subject>Precancerous Conditions - pathology</subject><subject>Trans-Activators - genetics</subject><subject>Trans-Activators - metabolism</subject><subject>Tumors</subject><subject>β-catenin mutation</subject><issn>0022-3417</issn><issn>1096-9896</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1u1DAQxy0Eape2B14A5QKiUt167MRJjqvSbpFWdJGKOFqOM9Ea8lU7K7rPwZvAe_SZcHYjygVx8njmNx_6_wl5BewcGOMXvR7W5yCAPSMzYLmkeZbL52QWapyKGNJD8tL7r4yxPE-SA3IIXIoERDYjP-ZF27lG13aw6KOuiq5opNsyWlGjyzU62-6-Rg_Yhvjd4096Fj3-olPibFftgTMztKcRPvQOvbddGwUY27JrcHBW12FAa9Dt6L_Tetj21oRgve3R9bX2Vh-TF5WuPZ5M7xH5fH11d3lDl7eLD5fzJTVxJhkVstRlUsRZlcbaFDwvdGyQ56LCSvDCJJybSgBkWGYphziDioPRWKbJKIMWR-Ttfm7vuvsN-kE11husa91it_EqFSzoCPBfELI0kXGSBvB0DxrXee-wUr2zjXZbBUyNVqnRKjVaFdjX09BN0WD5RE7eBODNBGgfFKpcUND6Jy6WEI4bl17sue-2xu2_N6rV_O5mWk33HdYP-PCnQ7tvSqYiTdSXjwslVwt4fy2X6pP4DaJovBY</recordid><startdate>200304</startdate><enddate>200304</enddate><creator>Moreno-Bueno, Gema</creator><creator>Hardisson, David</creator><creator>Sarrió, David</creator><creator>Sánchez, Carolina</creator><creator>Cassia, Raúl</creator><creator>Prat, Jaime</creator><creator>Herman, James G</creator><creator>Esteller, Manel</creator><creator>Matías-Guiu, Xavier</creator><creator>Palacios, José</creator><general>John Wiley &amp; Sons, Ltd</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200304</creationdate><title>Abnormalities of E- and P-cadherin and catenin (β-, γ-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia</title><author>Moreno-Bueno, Gema ; Hardisson, David ; Sarrió, David ; Sánchez, Carolina ; Cassia, Raúl ; Prat, Jaime ; Herman, James G ; Esteller, Manel ; Matías-Guiu, Xavier ; Palacios, José</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4860-36dad5b48f74acb29ba4ce293fef32bc522cf3118ed8721481f21caed759955a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>atypical endometrial hyperplasia</topic><topic>beta Catenin</topic><topic>Biological and medical sciences</topic><topic>Cadherins - metabolism</topic><topic>catenin</topic><topic>Catenins</topic><topic>Cell Adhesion Molecules - metabolism</topic><topic>Cytoskeletal Proteins - genetics</topic><topic>Cytoskeletal Proteins - metabolism</topic><topic>Disease Progression</topic><topic>E-cadherin</topic><topic>endometrial cancer</topic><topic>Endometrial Hyperplasia - genetics</topic><topic>Endometrial Hyperplasia - metabolism</topic><topic>Endometrial Hyperplasia - pathology</topic><topic>Endometrial Neoplasms - genetics</topic><topic>Endometrial Neoplasms - metabolism</topic><topic>Endometrial Neoplasms - pathology</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Loss of Heterozygosity</topic><topic>Medical sciences</topic><topic>Mutation</topic><topic>Neoplasm Proteins - metabolism</topic><topic>P-cadherin</topic><topic>Phosphoproteins - metabolism</topic><topic>Precancerous Conditions - genetics</topic><topic>Precancerous Conditions - metabolism</topic><topic>Precancerous Conditions - pathology</topic><topic>Trans-Activators - genetics</topic><topic>Trans-Activators - metabolism</topic><topic>Tumors</topic><topic>β-catenin mutation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moreno-Bueno, Gema</creatorcontrib><creatorcontrib>Hardisson, David</creatorcontrib><creatorcontrib>Sarrió, David</creatorcontrib><creatorcontrib>Sánchez, Carolina</creatorcontrib><creatorcontrib>Cassia, Raúl</creatorcontrib><creatorcontrib>Prat, Jaime</creatorcontrib><creatorcontrib>Herman, James G</creatorcontrib><creatorcontrib>Esteller, Manel</creatorcontrib><creatorcontrib>Matías-Guiu, Xavier</creatorcontrib><creatorcontrib>Palacios, José</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moreno-Bueno, Gema</au><au>Hardisson, David</au><au>Sarrió, David</au><au>Sánchez, Carolina</au><au>Cassia, Raúl</au><au>Prat, Jaime</au><au>Herman, James G</au><au>Esteller, Manel</au><au>Matías-Guiu, Xavier</au><au>Palacios, José</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abnormalities of E- and P-cadherin and catenin (β-, γ-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia</atitle><jtitle>The Journal of pathology</jtitle><addtitle>J. Pathol</addtitle><date>2003-04</date><risdate>2003</risdate><volume>199</volume><issue>4</issue><spage>471</spage><epage>478</epage><pages>471-478</pages><issn>0022-3417</issn><eissn>1096-9896</eissn><coden>JPTLAS</coden><abstract>Abnormal expression of cadherins and catenins plays a critical role in the initiation and progression of multiple human tumours. This study aimed to evaluate the immunoreactivity of E‐ and P‐cadherin, β‐ and γ‐catenin, and p120ctn in premalignant and malignant endometrial lesions and to correlate their membranous expression with clinicopathological features. In addition, we examined whether or not LOH and promoter hypermethylation of the CDH1 gene were associated with E‐cadherin expression and clinicopathological variables. Finally, we studied the frequency of β‐catenin mutations in premalignant endometrial lesions. Immunohistochemical staining was performed in 21 atypical endometrial hyperplasias (AEHs), 95 endometrioid carcinomas (EECs), and 33 non‐endometrioid carcinomas (NEECs). Reduced E‐cadherin expression was observed in 57.8% of the cases, being more frequent in NEECs (87.1%, p = 0.001) and carcinomas of more advanced stage (85.7% of stage III–IV carcinomas, p = 0.01). LOH of CDH1 gene was found in 57.1% of NEECs but only in 22.5% of EECs (p = 0.011) and showed a trend towards association with reduced E‐cadherin expression (p = 0.089). CDH1 promoter hypermethylation was found in 21.2% of endometrial carcinomas but was not associated with clinicopathological or immunohistochemical variables. Reduced expression of β‐ and γ‐catenin and p120ctn was found in 76.1%, 94.3%, and 63.6% of the cases, respectively, being more frequent in lesions with reduced E‐cadherin expression. In addition, β‐catenin, but not γ‐catenin or p120ctn expression, was associated with the histology of the lesion, since it was reduced in 35% of AEHs, 80.3% of EECs, and 96.9% of NEECs (p = 0.000). Mutations in exon 3 of the β‐catenin gene, associated with β‐catenin nuclear expression, were detected in 3 (14.0%) AEH, a frequency similar to that previously reported in this series of ECs. Finally, upregulation of P‐cadherin was observed in 28.6% of cases. This alteration was associated with the histology of the lesion, since it was found in 9.5% of AEHs, 27.7% of EECs, and 46.2% of NEECs (p = 0.021). Copyright © 2003 John Wiley &amp; Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Ltd</pub><pmid>12635138</pmid><doi>10.1002/path.1310</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-3417
ispartof The Journal of pathology, 2003-04, Vol.199 (4), p.471-478
issn 0022-3417
1096-9896
language eng
recordid cdi_proquest_miscellaneous_73089611
source MEDLINE; Wiley Online Library
subjects atypical endometrial hyperplasia
beta Catenin
Biological and medical sciences
Cadherins - metabolism
catenin
Catenins
Cell Adhesion Molecules - metabolism
Cytoskeletal Proteins - genetics
Cytoskeletal Proteins - metabolism
Disease Progression
E-cadherin
endometrial cancer
Endometrial Hyperplasia - genetics
Endometrial Hyperplasia - metabolism
Endometrial Hyperplasia - pathology
Endometrial Neoplasms - genetics
Endometrial Neoplasms - metabolism
Endometrial Neoplasms - pathology
Female
Female genital diseases
Gynecology. Andrology. Obstetrics
Humans
Loss of Heterozygosity
Medical sciences
Mutation
Neoplasm Proteins - metabolism
P-cadherin
Phosphoproteins - metabolism
Precancerous Conditions - genetics
Precancerous Conditions - metabolism
Precancerous Conditions - pathology
Trans-Activators - genetics
Trans-Activators - metabolism
Tumors
β-catenin mutation
title Abnormalities of E- and P-cadherin and catenin (β-, γ-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T17%3A22%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abnormalities%20of%20E-%20and%20P-cadherin%20and%20catenin%20(%CE%B2-,%20%CE%B3-catenin,%20and%20p120ctn)%20expression%20in%20endometrial%20cancer%20and%20endometrial%20atypical%20hyperplasia&rft.jtitle=The%20Journal%20of%20pathology&rft.au=Moreno-Bueno,%20Gema&rft.date=2003-04&rft.volume=199&rft.issue=4&rft.spage=471&rft.epage=478&rft.pages=471-478&rft.issn=0022-3417&rft.eissn=1096-9896&rft.coden=JPTLAS&rft_id=info:doi/10.1002/path.1310&rft_dat=%3Cproquest_cross%3E73089611%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18756457&rft_id=info:pmid/12635138&rfr_iscdi=true